Corticosteroids in COVID-19: one size does not fit all

E dalatifard et al. [1], in a single-blind randomised controlled clinical trial, showed that methylprednisolone pulse administration (250 mg per day intravenously for 3 days) to hospitalised, not intubated patients with severe coronavirus disease 2019 (COVID-19), significantly improved survival and duration of recovery compared to standard care; the effect was more prominent in patients receiving noninvasive ventilation and reservoir mask support. Organising pneumonia and acute fibrinous and organising pneumonia have been reported as the predominant patterns in pathological samples from COVID-19 patients. Critically ill COVID-19 patients may benefit even more from higher corticosteroid doses. https://bit.ly/3timqPM